Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/113988
Campo DC Valoridioma
dc.contributor.authorUter, Wen_US
dc.contributor.authorWilkinson, SMen_US
dc.contributor.authorAerts, Oen_US
dc.contributor.authorBauer, Aen_US
dc.contributor.authorBorrego Hernando, Leopoldoen_US
dc.contributor.authorBuhl, Ten_US
dc.contributor.authorCooper, SMen_US
dc.contributor.authorDickel, Hen_US
dc.contributor.authorGallo, Ren_US
dc.contributor.authorGimenez-Arnau, AMen_US
dc.contributor.authorJohn, SMen_US
dc.contributor.authorNavarini, AAen_US
dc.contributor.authorPesonen, Men_US
dc.contributor.authorPonyai, Gen_US
dc.contributor.authorRustemeyer, Ten_US
dc.contributor.authorSchliemann, Sen_US
dc.contributor.authorSchubert, Sen_US
dc.contributor.authorSchuttelaar, MLAen_US
dc.contributor.authorValiukeviciene, Sen_US
dc.contributor.authorWagner, Nen_US
dc.contributor.authorWeisshaar, Een_US
dc.contributor.authorGoncalo, Men_US
dc.date.accessioned2022-03-09T14:30:24Z-
dc.date.available2022-03-09T14:30:24Z-
dc.date.issued2022en_US
dc.identifier.issn0105-1873en_US
dc.identifier.urihttp://hdl.handle.net/10553/113988-
dc.description.abstractBackground: In 2019, a number of allergens (haptens), henceforth, “the audit allergens,” were considered as potential additions to the European Baseline Series (EBS), namely, sodium metabisulfite, 2-bromo-2-nitropropane-1,3-diol, diazolidinyl urea, imidazolidinyl urea, Compositae mix II (2.5% or 5% pet), linalool hydroperoxides (lin-OOH), limonene hydroperoxides (lim-OOH), benzisothiazolinone (BIT), octylisothiazolinone (OIT), decyl glucoside, and lauryl glucoside; Evernia furfuracea (tree moss), was additionally tested by some departments as well. Objectives: To collect further data on patch test reactivity and clinical relevance of the audit allergens in consecutive patients across Europe. Methods: Patch test data covering the audit allergens in 2019 and 2020 were collected by those departments of the European Surveillance System on Contact Allergies testing these, as well as further collaborators from the EBS working group of the European Society of Contact Dermatitis (ESCD), and the Spanish Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea. As patch test outcome, reactions between day (D) 3 and D5 were considered. Results: Altogether n = 12 403 patients were tested with any of the audit allergen. Positive reactions were most common to lin-OOH 1% pet. (8.74% [95%CI: 8.14–9.37%]), followed by lin-OOH 0.5% pet., and lim-OOH 0.3% pet (5.41% [95% CI: 4.95–5.89%]). Beyond these terpene hydroperoxides, BIT 0.1% pet. was the second most common allergen with 4.72% (95% CI: 4.2–5.28%), followed by sodium metabisulfite 1% pet. (3.75% [95%CI: 3.32–4.23%]) and Compositae mix 5% pet. (2.31% [95% CI: 1.84–2.87%]). For some allergens, clinical relevance was frequently difficult to ascertain. Conclusions: Despite many positive patch test reactions, it remains controversial whether lin- and lim-OOH should be tested routinely, while at least the two preservatives BIT and sodium metabisulfite appear suitable. The present results are a basis for further discussion and ultimately decision on their implementation into routine testing among the ESCD members.en_US
dc.languageengen_US
dc.relation.ispartofContact Dermatitisen_US
dc.sourceContact Dermatitis [ISSN 0105-1873], v. 86(5), p. 379-389en_US
dc.subject32 Ciencias médicasen_US
dc.subject320106 Dermatologíaen_US
dc.subject320701 Alergiasen_US
dc.subject.otherBaseline seriesen_US
dc.subject.otherBenzisothiazolinoneen_US
dc.subject.otherClinical epidemiologyen_US
dc.subject.otherContact allergyen_US
dc.subject.otherDecyl glucosideen_US
dc.subject.otherPatch testingen_US
dc.subject.otherRRIDen_US
dc.subject.otherSCR_001905en_US
dc.subject.otherSodium metabisulfiteen_US
dc.subject.otherSurveillanceen_US
dc.titleEuropean patch test results with audit allergens as candidates for inclusion in the European Baseline Series, 2019/20: Joint results of the ESSCA(A) and the EBSB working groups of the ESCD, and the GEIDAC(C)en_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typearticleen_US
dc.identifier.doi10.1111/cod.14059en_US
dc.identifier.pmid35099073-
dc.identifier.scopus2-s2.0-85125074513-
dc.identifier.isiWOS:000756887100001-
dc.contributor.orcid0000-0002-4498-3710-
dc.contributor.orcid0000-0001-7253-3461-
dc.contributor.orcid0000-0002-0076-2887-
dc.contributor.orcid0000-0002-4411-3088-
dc.contributor.orcid0000-0002-0199-2756-
dc.contributor.orcid0000-0002-3139-129X-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid0000-0002-1735-4425-
dc.contributor.orcid0000-0001-5434-7753-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid0000-0003-0356-7064-
dc.contributor.orcid0000-0002-1695-6133-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid0000-0002-0766-4382-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid0000-0001-6842-1360-
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.notasPPRC-2018-8 European Academy of Dermatovenerology (EADV)en_US
dc.description.numberofpages11en_US
dc.utils.revisionen_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr0,72
dc.description.jcr5,5
dc.description.sjrqQ1
dc.description.jcrqQ1
dc.description.scieSCIE
dc.description.miaricds11,0
item.grantfulltextopen-
item.fulltextCon texto completo-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-0199-2756-
crisitem.author.fullNameBorrego Hernando, Leopoldo-
Colección:Artículos
miniatura
Adobe PDF (1,76 MB)
Vista resumida

Citas SCOPUSTM   

27
actualizado el 24-nov-2024

Citas de WEB OF SCIENCETM
Citations

27
actualizado el 24-nov-2024

Visitas

119
actualizado el 25-may-2024

Descargas

109
actualizado el 25-may-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.